Drug or intervention
Radiation Clinical Trials
Studies that test Radiation, alone, with other treatments or as the comparison.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 5,145Esophageal Squamous Cell Carcinoma, Immunotherapy
Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC
To evaluate the efficacy and safety of adebrelimab with or without induction chemotherapy followed by concurrent chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma
- Conditions
- Esophageal Squamous Cell Carcinoma, Immunotherapy, Biomarkers
- Trial name
- RICE (NCT06510660)
- Testing
- adebrelimab
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Fujian Medical University Union Hospital
Ganglioneuroblastoma, Nodular, Neuroblastoma
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
This phase III trial tests how well the addition of dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy works for…
- Trial name
- NCT06172296
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- 180 sites in United States, Australia and 3 more
- Volunteers
- 478 people
- Sponsor
- National Cancer Institute (NCI)
Healthy Volunteer, Malaria
Positron Emission Tomography and Organ-Specific Changes in Participants Co-Enrolled in NIH Studies of Plasmodium Vivax Controlled Human Malaria Infection
Background: Malaria is a serious disease caused by parasites spread by mosquitoes. To better diagnose and treat malaria, researchers need to learn more about where the parasites go when they enter a person's body.
- Trial name
- NCT07859800
- Testing
- 18F-fluorodeoxyglucose-positron emission tomography/computed tomography scan
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
B-Cell Acute Lymphoblastic Leukaemia
International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)
The IntReALL BCP 2020 study aims to review recent developments and findings regarding chemoimmunotherapy with inotuzumab and immunotherapy with blinatumomab and to increase the use of promising new immunotherapeutic drugs as…
- Trial name
- NCT07476729
- Testing
- Inotuzumab ozogamicin (INO), Blinatumomab
- Where
- 21 sites in Austria, Belgium and 19 more
- Volunteers
- 750 people
- Sponsor
- Charite University, Berlin, Germany
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the course of…
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related
- Trial name
- NCT05564390
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Best Practice
- Where
- 360 sites in United States, Canada and 1 more
- Volunteers
- 2,000 people
- Sponsor
- National Cancer Institute (NCI)
Healthy Subjects
Prospective Evaluation of Next Generation CT Reconstruction (NextGenIR)
Background: Computed Tomography (CT) is a scan that makes detailed pictures of the body. It uses radiation to do that. In 2011, about 85.3 million CT scans were done in the United States.
- Trial name
- NCT02417714
- Where
- United States
- Volunteers
- 215 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Core Binding Factor Alpha Subunits, Hematologic Neoplasms
Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers
Background: Some blood cancers can be caused by germline variants (changes) in a person s RUNX1 gene. Germline variants are genetic inherited changes a person is born with.
- Conditions
- Core Binding Factor Alpha Subunits, Hematologic Neoplasms, Leukemia, Lymphoma
- Trial name
- NCT07524530
- Testing
- Cyclophosphamide, Busulfan, Fludarabine
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- National Cancer Institute (NCI)
Adrenocortical Carcinoma (ACC), Recurrent Adrenocortical Carcinoma (ACC)
Study of Preoperative Radiation Therapy in Participants With Resectable Recurrent Abdominal Adrenocortical Carcinoma
Background: Adrenocortical carcinoma (ACC) is a rare cancer of the adrenal glands. ACC often returns after tumors are removed with surgery. Less than 35% of people with ACC survive 5 years after diagnosis.
- Conditions
- Adrenocortical Carcinoma (ACC), Recurrent Adrenocortical Carcinoma (ACC), Recurrent Abdominal Adrenocortical Carcinoma (ACC), Carcinoma, Adrenocortical
- Trial name
- NCT06487481
- Testing
- Surgical resection, Preoperative RT
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma (HCC)
Personalized Adaptive Radiotherapy for Hepatocellular Carcinoma
This study evaluates whether Personalized Ultrafractionated Stereotactic Adaptive Radiation Therapy (PULSAR) improves overall survival compared with best supportive care (BSC).
- Trial name
- PULSAR-HCC (NCT07895732)
- Testing
- Best Supportive Care (BSC), Personalized ultrafractionated stereotactic adaptive radiation therapy (PULSAR)
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- University Health Network, Toronto
Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer
This phase II trial tests the addition of chemotherapy, with carboplatin and paclitaxel, or chemo-immunotherapy, with carboplatin, paclitaxel and cemiplimab to standard salvage surgery followed by post operative radiation therapy…
- Conditions
- Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Locally Recurrent Head and Neck Squamous Cell Carcinoma, Locally Recurrent Hypopharyngeal Squamous Cell Carcinoma
- Trial name
- NCT07195734
- Testing
- Biospecimen Collection, Carboplatin, Cemiplimab
- Where
- 115 sites in United States
- Volunteers
- 180 people
- Sponsor
- National Cancer Institute (NCI)
Completed, with results posted
All 2,141Larynx, Lip
Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN
The purpose of this study is to investigate other drugs that may be combined with radiation to treat cancer. The study focuses on determining whether a combination of durvalumab with radiation can both improve cure rate and at…
- Conditions
- Larynx, Lip, Oral Cancer, Digestive Organs--Diseases
- Trial name
- NCT03529422
- Testing
- Durvalumab, Intensity Modulated Radiotherapy Treatments
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Head and Neck Squamous Cell Carcinoma
An Experimental Study to Compare Treatment Response and Toxicities of Concurrent Chemoradiation With Weekly Cisplatin and Three Weekly Cisplatin in Locally Advanced Head and Neck Cancer.
The aim of this study is to compare treatment responses and toxicities of concurrent chemo-radiation with weekly and three weekly Cisplatin in locally advanced Head \& Neck Cancer.
- Trial name
- HNC (NCT03998696)
- Testing
- Cisplatin 40 mg/m2, Cisplatin 100 mg/m2
- Where
- Bangladesh
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Lymphoma, B-Cell, Relapsed Cancer
Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T)
Participants are invited to take part in this research study because they have relapsed (cancer has come back) or refractory (cancer has not responded to treatment) B-cell Lymphoma and will be undergoing CAR T-cell Therapy.
- Conditions
- Lymphoma, B-Cell, Relapsed Cancer, Refractory Lymphoma, Diffuse Large B Cell Lymphoma
- Trial name
- NCT06004167
- Testing
- Adaptive Bridging Radiation Therapy (ABRT)
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Massachusetts General Hospital
Stage I Prostate Adenocarcinoma, Stage II Prostate Adenocarcinoma
Stereotactic Body Radiation Therapy With Boost Using Urethral-Sparing Intensity-Modulated Radiation Therapy Planning in Treating Patients With Prostate Cancer
This phase I/II trial studies the side effects and best dose of stereotactic body radiation therapy while using intensity-modulated radiation therapy (IMRT) planning to help avoid radiation to normal tissue in patients with…
- Trial name
- NCT02470897
- Testing
- Radiation Therapy Treatment Planning and Simulation, SBRT
- Where
- 3 sites in United States
- Volunteers
- 115 people
- Sponsor
- University of Wisconsin, Madison
Advanced Breast Carcinoma, HER2-Positive Breast Carcinoma
TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer
This phase II trial studies how well FASN inhibitor TVB-2640, paclitaxel, and trastuzumab work in treating patients with HER2 positive breast cancer that has spread to other places in the body (metastatic).
- Conditions
- Advanced Breast Carcinoma, HER2-Positive Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8
- Trial name
- NCT03179904
- Testing
- Anastrozole, Denifanstat, Exemestane
- Where
- 3 sites in United States
- Volunteers
- 17 people
- Sponsor
- Mayo Clinic